Pope Francis (Credit: X)
Pope Francis injured his right arm after suffering a fall earlier this week. According to the Vatican, while the 88-year-old pontiff did not break his arm, a sling was put on as a precaution. This incident comes just weeks after another fall on December 7, where he hit his chin on a nightstand, resulting in another, visible bruise. The pope's health has been a topic of ongoing speculation due to his age and medical history, which includes long bouts of bronchitis and mobility challenges. Often seen using a wheelchair or a cane, Francis also uses a walker within the Vatican's Santa Marta hotel, where he resides. Notably, his frailty has brought renewed attention to the risks of falls among elderly individuals and the steps one must follow to mitigate such falls.
A study published in Frontiers in Aging Neurosciences people get older, the bone density in the lower back and thigh bone decreases significantly. This raises the risk of osteoporosis (OP). Therefore it becomes pivotal to pay early attention to nutrition, exercise ability, vitamin D levels, and uric acid levels in older individuals to prevent Ostreopsis and mitigate fall risks. The risk of falls and bone injuries among elderly individuals underscores the importance of preventive measures for maintaining bone health and minimizing fall risks.
Elderly, particularly menopausal women, require a daily calcium intake of 1,200 mg, divided into two or more doses. This can be achieved through dietary sources such as dairy and non-dairy products or through supplements like calcium carbonate and calcium citrate. However, total daily calcium intake should not exceed 2,500 mg to avoid potential health risks.
Vitamin D is essential for calcium absorption and bone mineralization. While sunlight exposure helps synthesize vitamin D, older individuals often require supplements due to reduced skin synthesis and the limited availability of foods. Fortified milk and supplements containing 200–600 IU of vitamin D daily are recommended, with higher doses required for those with deficiencies. Severe cases may necessitate high-dose treatments, such as 50,000 IU weekly for up to three months, along with regular monitoring of calcium and vitamin D levels.
Regular exercise is vital for preserving bone mass and reducing fall risk. Weight-bearing activities, strength training, and balance exercises like brisk walking or skipping can enhance bone density and improve coordination. Experts recommend at least 30 minutes of moderate physical activity most days of the week, supplemented by strength training twice weekly. For individuals unable to engage in standard exercise routines, alternatives like vibrating platforms may help maintain bone health.
Falls remain a leading cause of fractures among individuals over 60. Addressing contributing factors such as balance issues, vision problems, and environmental hazards can significantly reduce risks. Preventive measures include regular vision checks, minimizing medications causing dizziness, improving home safety (e.g., installing railings and removing loose rugs), and wearing rubber-soled footwear. Hip protectors may also help mitigate the impact of falls.
Credit: iStock
AI company Anthropic’s chatbot Claude has discovered a novel enzyme system with properties resembling CRISPR, a gene-editing technology.
The finding comes from Anthropic’s new life sciences research group and laboratory, established earlier this year to use Claude to explore DNA datasets, identify uncharacterized protein families and generate hypotheses for laboratory testing.
Anthropic said Claude autonomously identified an enzyme system associated with an array of DNA repeats, a pattern similar to CRISPR.
“Although we don’t yet know its function, the system that Claude discovered has a set of characteristics that have only ever been found together in a handful of other systems, all of which are programmable and perform operations like cutting, copying, and pasting DNA,” the company said in a blog post.
The system is based on reverse transcriptase (RT), an enzyme that copies RNA into DNA. Anthropic said Claude was the first to identify the combination of features defining the system, which researchers named array-associated reverse transcriptases (ART).
ART was identified in bacteriophages, viruses that infect bacteria, according to a preprint.
“These findings indicate that LLMs can autonomously detect anomalies and drive analyses to initiate biological discoveries,” the researchers said.
“This is an exciting example of how AI agents can contribute to biological discovery. The identification of RNA-repeat arrays associated with reverse transcriptases is genuinely intriguing and merits further investigation. I hope this work encourages more scientists to explore how AI can support their research,” said Feng Zhang, a CRISPR pioneer and professor at MIT and the Broad Institute, after reviewing the preprint.
Anthropic researchers prompted Claude to search a massive DNA database for unusual reverse transcriptases.
After 21 hours of searching by roughly 950 agents using 210 million tokens, one agent identified a repeating DNA sequence next to the gene for an unusual RT.
Further analysis and laboratory testing showed that the pattern marked a previously uncharacterized enzyme system in bacteriophages. Anthropic said research into ART’s function is ongoing.
It is too early to know whether ART can become a gene-editing tool, and researchers have not yet established what ART does or whether it can be programmed to make precise changes to DNA.
If future research shows that ART can recognize or manipulate specific genetic sequences, it could potentially offer another system for studying gene editing.
Its properties could also reveal new ways biological systems recognize, copy or modify genetic material, potentially leading to tools with capabilities different from existing CRISPR technologies.
For now, the key finding is that AI helped identify a previously uncharacterized biological system that can now be studied experimentally.
AI is increasingly being used in gene-editing research. In 2025, Stanford Medicine researchers reported CRISPR-GPT, an AI system designed to assist with gene-editing workflows, including generating designs, analyzing data and troubleshooting problems.
While CRISPR-GPT helps researchers use existing gene-editing tools, Claude’s latest discovery involves identifying a previously uncharacterized biological system.
The findings highlight a potential new role for AI in biology: helping researchers discover biological systems that could eventually become new research tools.
Credit: AI
The US Food and Drug Administration (FDA) could soon implement measures to speed up processes that help companies obtain approvals for new vaping products and nicotine pouches, according to a Reuters report that cited in a Wall Street Journal report.
The agency is expected to revisit rules introduced in 2021 to simplify some scientific requirements and shorten timelines of review of these products, allowing them to move through the approval process swiftly and smoothly.
It is important to note that Reuters could not verify the report independently. The FDA, too, had not responded to a request for a comment.
The development is slightly alarming as even though these products are often positioned as alternatives to traditional cigarettes, they are not essentially safer.
Most e-cigarettes contain nicotine, which is a highly addictive substance. The aerosol produced by a vape can also contain harmful substances, including cancer-causing chemicals, heavy metals like nickel, tin and lead, and other tiny particles that can travel into the lungs, leaving lasting damage.
It is also important to understand that the long-term effects of vaping are still being studied.
For adults who already smoke cigarettes, the FDA says switching completely to e-cigarettes may reduce damage that stem from harmful chemicals found in cigarette smoke.
But continuing to smoke while vaping, known as dual use, does not provide any benefit. Hence, FDA authorisation is not a declaration or proof that a product is risk-free.
Also read: Never Smoked, Still Got Lung Cancer? Rare Gene Mutation Linked To Over 60x Risk
Nicotine pouches do not produce smoke or an inhaled aerosol. Instead, the pouch is placed in the mouth, where nicotine is absorbed through the gums and lining of the mouth. Again, nicotine pouches may pose lesser risk than tobacco cigarettes, but it still contains nicotine.
The FDA says nicotine pouches can generally be a lower-risk alternative for adults who smoke cigarettes if they switch completely, because they can reduce exposure to many harmful chemicals found in cigarettes. But they are not risk-free, and the FDA has not approved nicotine pouches as medicines to help quit smoking.
The agency has already authorised some nicotine pouch products after reviewing their risks and benefits. In August 2026, it authorised four additional products through its nicotine pouch pilot programme.
Nicotine is highly addictive and can affect the brain, especially in the younger population. Nicotine pouches can also contain relatively high levels of nicotine, and scientists are still studying their short as well as long-term health effects.
Also read: It’s Not Just Tobacco: The Hidden Oral Cancer Risks We Rarely Talk About
The FDA's move is essentially about how quickly products can be reviewed and approved, not about removing the requirement that products meet a specific public-health standard.
The FDA says authorised products must prove that their benefits for the public as a whole is greater than the risks they pose.
At the same time, it continues to state that there are no safe tobacco products, and people who do not use tobacco should not start using vapes or nicotine pouches.
Credit: iStock
Cancer death rates among American men and women declined from 2019 to 2023, continuing a downward trend that has lasted more than 20 years, according to a new CDC report.
The 2026 Annual Report to the Nation on the Status of Cancer, published in the journal Cancer, found that the continued decline in cancer mortality was driven largely by sustained progress against lung cancer.
“Cancer incidence was stable among males but increased slowly among females. Cancer mortality continued to decline, largely because of sustained progress against lung cancer,” the report said.
The overall cancer death rate during 2019–2023 was 145.4 per 100,000. It was higher among males (171.5 per 100,000) than females (126.3 per 100,000)
Cancer death rates decreased among males and females of every race and ethnicity. From 2004 to 2023, the cancer death rate declined by:
Between 2019 and 2023, death rates among males decreased for 12 of the 18 most common cancers, remained stable for four and increased for two.
Among females, death rates decreased for 12 of the 19 most common cancers, remained stable for three and increased for four. The largest declines were seen in lung cancer and myeloma.
Lung cancer recorded the largest decline in cancer mortality between 2019 and 2023:
Lung cancer incidence also decreased between 2018 and 2022:
Researchers attributed the progress partly to:
Lung cancer remains the leading cause of cancer death among both men and women in the United States. It is also the second most commonly diagnosed cancer among men, after prostate cancer, and among women, after breast cancer.
While cancer mortality continued to decline, incidence trends were different.
Overall cancer incidence rates were 504.6 per 100,000 among males and 443.0 among females during 2018–2019 and 2021–2022. The year 2020 was excluded because of pandemic-related diagnostic delays.
Incidence rates:
Among males, stable overall incidence was driven by a decline in lung cancer, which offset an increase in prostate cancer.
Incidence decreased for cancers of the:
Rates increased for cancers of the oral cavity and pharynx and pancreas, while rates for seven of the 18 most common cancers remained stable.
Prostate cancer incidence increased while lung cancer incidence decreased among males across every race and ethnicity. Colorectal cancer incidence decreased among White males but remained stable among other males.
The report also examined trends in new U.S. cancer cases from 2003 to 2022. Overall cancer incidence rose slightly each year from 2018 to 2022, driven by increases in breast cancer among women and prostate cancer among men.
Breast and prostate cancer remained the most commonly diagnosed cancers among women and men, respectively.
Despite the increase in prostate cancer, the overall rate of new cancer cases among men remained stable.
The report also noted that continued progress in cancer prevention and control will depend on tobacco-free environments, preventive care, screening, timely diagnosis, state-of-the-art treatment and survivorship care.
© $2026 Times Horizon Private Limited